Jumpstarting Research: Big Pharma's Out-Licensing Dilemma

At Windhover's Jumpstart to Products Conference, a number of speakers, including Merck's head of basic research, argued--at least by implication--that Big Pharma needs to do more of the kinds of reformulations and re-indications of existing compounds that net them products faster and with less risk--that allow them to "jumpstart" R&D. For biotechs pursuing a similar strategy, getting starter material--in the form of compounds Pharma has abandoned--is crucial, though few Pharmas are willing to out-license. Lilly is the great exception to this rule: the company's Joe Zakrzewski argues why outlicensing is critical to his firm's success.

We just can't afford to be who we were. This was the fundamental subtext behind everything Anthony Ford-Hutchinson, PhD, EVP and head of basic research for Merck & Co. Inc. told the audience at Windhover's Jumpstart to Products Conference in San Francisco, March 3-4.

In slide after slide, Ford-Hutchinson detailed the kinds of reformulations, re-indications and out-partnering that Merck has done little of in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo